Videos

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.

This episode of Lungcast features a discussion on emerging research in lung cancer biomarkers and early detection.

At SLEEP 2025, Cassiere discussed how pulse oximetry inaccuracies among patients with darker skin tones may lead to underdiagnosis or misclassification of sleep apnea severity.

At SLEEP 2025, Lillis discussed how wearable data revealed disruptions in sleep consolidation up to 13 weeks postpartum despite total sleep duration nearing pre-pregnancy levels.

Melinda Gooderham, MD, MSc, joins The Medical Sisterhood to discuss balancing mentorship, leadership, and family, as well as the empowerment of women in the medical field.

By week 2 postpartum, sleep duration rebounds, but fragmented sleep persists through week 13, Teresa Lillis, PhD, presented at SLEEP 2025.

At SLEEP 2025, Walia discussed findings showing Hispanic individuals may experience more severe cases of sleep disordered breathing compared to the non-Hispanic group.

At SLEEP 2025, Winkelman discussed the AASM’s updated guidelines urging clinicians to transition patients with RLS off dopamine agonists due to augmentation risks.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This June 17, 2025 SOCS News Update highlights creating strategic plans with mentors and mentees.

At SLEEP 2025, Kancherla highlights diagnostic dilemmas, treatment gaps, and the need for pediatric criteria when managing obstructive sleep apnea in teens.

At SLEEP 2025, Kancherla emphasized the importance of using pediatric criteria to manage OSA in adolescents, warning that adult standards may overlook key developmental factors.

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

Preston describes lasting unmet needs in pulmonary arterial hypertension and reviews new pooled data supporting sotatercept’s long-term safety and efficacy.

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.

At SLEEP 2025, Fung shared that masked taper plus CBT-I led to higher benzodiazepine discontinuation and improved sleep in older adults.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.